Inhibition of CXCR4 also showed promise, with pre-clinical testing of Plerixafor reducing the establishment of bone metastases in bone-metastatic prostate cancer mouse models, yet it failed to impact the growth of pre-established bone metastases (243). This evidence concerns the gene CXCR4 and prostate cancer.